Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial
Publication
, Conference
Karukonda, P; Czito, BG; Duffy, E; Uronis, HE; D'Amico, TA; Strickler, JH; Niedzwiecki, D; Willett, C; Palta, M
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Karukonda, P., Czito, B. G., Duffy, E., Uronis, H. E., D’Amico, T. A., Strickler, J. H., … Palta, M. (2023). Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Karukonda, Pooja, Brian G. Czito, Eileen Duffy, Hope Elizabeth Uronis, Thomas A. D’Amico, John H. Strickler, Donna Niedzwiecki, Christopher Willett, and Manisha Palta. “Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Karukonda P, Czito BG, Duffy E, Uronis HE, D’Amico TA, Strickler JH, et al. Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Karukonda, Pooja, et al. “Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.
Karukonda P, Czito BG, Duffy E, Uronis HE, D’Amico TA, Strickler JH, Niedzwiecki D, Willett C, Palta M. Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial. JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences